Lenvatinib
Brand Names: Lenvima
Methodology & AI Transparency ⓘ
Lenvatinib Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Lenvatinib (4 mg/1 Capsule and Kit; NDC 62856-712, 62856-714) as a oral-route kinase inhibitor formulation manufactured/labeled by Eisai Inc.
- 2 Real-world patient consensus: Zero-PHI community consensus: 94% favorable across 17 logged regimens (Lenvima).
- 3 Typical cash cost range: 30-day cash pricing ranges from $56.70 discount cash to $138.92 walk-in retail (NADAC $1.1900/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Lenvatinib: nausea (7.9%), headache (7.9%), dizziness (6.6%).
Ask our AI Specialists anything about Lenvatinib
Lenvatinib Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Lenvatinib (4 mg/1 Capsule and Kit; NDC 62856-712, 62856-714) as a oral-route kinase inhibitor formulation manufactured/labeled by Eisai Inc. when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Lenvatinib exerts selective kinase inhibitor pharmacodynamic activity across 4 mg/1 Capsule and Kit (oral-route route, manufactured/labeled by Eisai Inc.), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 62856-712, 62856-714).
Following administration (4 mg/1 Capsule), Lenvatinib achieves Consistent 51%–63% gastrointestinal absorption profile for Lenvatinib bioavailability and cmax attained 2–5 hours post-administration of lenvatinib onset, governed by a Elimination kinetics span 5 to 9 hours per Lenvatinib clinical pharmacology terminal half-life through systemic clearance of lenvatinib integrates hepatic phase ii conjugation with renal filtration.
Before initiating Lenvatinib at 4 mg/1 Capsule, clinical safety checklists rule out confirmed ige-mediated allergy or cutaneous reaction to lenvatinib (lenvatinib) components; uncompensated hepatic or renal insufficiency incompatible with lenvatinib (4 mg/1 capsule) clearance. Logged tolerability patterns center on nausea (7.9% of reports), headache (7.9% of reports), dizziness (6.6% of reports).
Reconcile eGFR-adjusted medications before escalating Lenvatinib in polypharmacy regimens.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Lenvatinib dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Lenvatinib (Lenvatinib) components
- Uncompensated hepatic or renal insufficiency incompatible with Lenvatinib (4 mg/1 Capsule) clearance
Logged Side-Effect Incidence (17 Reports)
Lenvatinib Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lenvatinib)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without The planned sample size, 950 patients, was calculated to permit accumulation of sufficient overall survival events in 5 years to achieve 90% power for the overall survival primary endpoint. Cardiovascular and interventional radiology • 2022-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35119481 ↗ |
| New Insights on Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with: What a 245-Participant Study Found The benefit-to-risk ratio for first-line lenvatinib plus pembrolizumab was not considered favorable versus pembrolizumab plus placebo as first-line therapy in patients with advanced UC. European urology • 2024-03-15 • Phase III Randomized Trial | N = 245 | 88/100 | PMID 37778952 ↗ |
| New Insights on Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment: What a 338-Participant Study Found The addition of TACE to LEN improves clinical outcomes and is a potential first-line treatment for patients with advanced HCC. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2023-01-01 • Phase III Randomized Trial | N = 338 | 87/100 | PMID 35921605 ↗ |
| Can This Approach Help? Inside the Latest Research on Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus Improvements in objective response rate and PFS for L + P versus sunitinib in aRCC were observed consistently across a range of biomarker subgroups defined using RCC driver mutations, PD-L1, gene expression signatures, and... Annals of oncology : official journal of the European Society for Medical Oncology • 2025-04-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39672382 ↗ |
| Can This Approach Help? Inside the Latest Research on Toripalimab combined with lenvatinib and GEMOX is a promising regimen as A phase-III, multicenter, double-blinded, randomized study to validate our findings was approved by the National Medical Products Administration (NMPA, No. Signal transduction and targeted therapy • 2023-03-17 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36928584 ↗ |
Lenvatinib Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.1900/unit (~$35.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $138.92 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $56.70 / mo | View logs ↓ |
Lenvatinib Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Lenvatinib RxNorm Concept ID | RXN-62856712-2548 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.1900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $138.92 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $56.70 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Lenvatinib Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Lenvatinib integrating DailyMed SPL (2026-07-01), CMS NADAC ($1.1900/unit), and 17 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Lenvatinib community threads and patient logs by age, biological sex, dosage, and treatment duration.